February 20, 2019

Export Manufacturing Waiver for Supplementary Protection Certificates: a red flag for investment in EU healthcare biotech

As the Association representing the European biotechnology industry, EuropaBio is fully committed to the development of a legislative environment which facilitates the creation of EU jobs and growth as well as new solutions to healthcare challenges.
November 29, 2017

European Commission launches: “What I need to know about Biosimilar Medicines – Information for patients”, in 23 EU languages

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
June 6, 2017

EuropaBio launches recommendations to enhance transparency of biosimilar labels

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
May 27, 2017

Biosimilar SmPC Recommendations

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
January 23, 2017

European Commission Initiative Improves Information for Patients on Biosimilar Medicines

European Commission Initiative Improves Information for Patients on Biosimilar Medicines.
Become a member